Skip to main content

Table 2 Genome-wide scan of DNA methylation for an association with fasting insulin concentrations (as a continuous variable)

From: DNA methylation in peripheral blood leukocytes for the association with glucose metabolism and invasive breast cancer

Chr

CpG site§

Position

Discovery

Validation

Meta-analysis

CpG context

Gene

Gene region

Effect† (95% CI)

Effect (95% CI)

p

Effect (95% CI)

p

pQÂ¥

chr1

cg05399785

3,564,031

2.49 (1.58, 3.40)

0.93 (− 2.51, 4.36)

0.592

2.38 (1.50, 3.27)

1.17E-07

0.383

N Shelf

WDR8

Body

chr1

cg09823288

239,552,128

− 1.15 (− 1.56, − 0.74)

− 2.62 (− 4.21, − 1.03)

0.001

− 1.24 (− 1.64, − 0.85)

8.92E-10

0.074

S Shore

 

Intergenic

chr1

cg14476101

120,255,992

− 1.27 (− 1.67, − 0.87)

− 2.65 (− 4.22, − 1.07)

0.001

− 1.35 (− 1.74, − 0.97)

4.55E-12

0.093

S Shore

PHGDH

Body

chr1

cg16246545

120,255,941

− 1.39 (− 1.92, − 0.87)

− 2.13 (− 4.06, − 0.20)

0.031

− 1.45 (− 1.95, − 0.94)

2.01E-08

0.466

S Shore

PHGDH

Body

chr1

cg17901584*

55,353,706

− 1.79 (− 2.39, − 1.19)

− 2.47 (− 4.60, − 0.35)

0.023

− 1.84 (− 2.42, − 1.27)

3.75E-10

0.541

S Shore

DHCR24

TSS1500

chr1

cg19693031

145,441,552

− 1.55 (− 2.05, − 1.05)

− 2.57 (− 4.17, − 0.96)

0.002

− 1.64 (− 2.12, − 1.17)

1.51E-11

0.230

OpenSea

TXNIP

3'UTR

chr4

cg06690548

139,162,808

− 1.30 (− 1.79, − 0.80)

− 3.51 (− 5.58, − 1.44)

0.001

− 1.42 (− 1.90, − 0.94)

7.80E-09

0.038

OpenSea

SLC7A11

Body

chr6

cg17501210

166,970,252

− 1.41 (− 1.93, − 0.89)

− 3.53 (− 5.87, − 1.19)

0.004

− 1.51 (− 2.02, − 1.00)

5.67E-09

0.079

OpenSea

RPS6KA2

Body

chr7

cg19390658*

30,636,176

− 1.18 (− 1.62, − 0.74)

− 1.03 (− 2.43, 0.38)

0.150

− 1.17 (− 1.59, − 0.74)

6.22E-08

0.836

S Shore

GARS

Body

chr8

cg00163372

128,752,988

1.86 (1.15, 2.58)

0.11 (− 1.98, 2.21)

0.915

1.67 (1.00, 2.35)

1.18E-06

0.116

S Shore

MYC

Body

chr9

cg15551881**

123,688,715

1.89 (1.22, 2.56)

1.64 (− 0.21, 3.49)

0.081

1.86 (1.23, 2.49)

7.39E-09

0.801

N Shelf

TRAF1

5'UTR

chr10

cg26712428**

105,218,771

2.31 (1.42, 3.19)

1.51 (− 1.14, 4.16)

0.260

2.22 (1.39, 3.06)

1.77E-07

0.572

S Shore

CALHM1

TSS200

chr11

cg00574958

68,607,622

− 6.76 (− 8.56, − 4.96)

− 6.57 (− 10.53, − 2.62)

0.001

− 6.73 (− 8.36, − 5.10)

6.42E-16

0.932

N Shore

CPT1A

5'UTR

chr13

cg19750657

38,935,967

1.93 (1.28, 2.58)

2.28 (− 0.39, 4.96)

0.093

1.95 (1.32, 2.58)

1.12E-09

0.799

OpenSea

UFM1

3'UTR

chr15

cg06192883**

52,554,171

2.64 (1.83, 3.45)

2.77 (0.45, 5.09)

0.020

2.66 (1.90, 3.42)

8.08E-12

0.919

OpenSea

MYO5C

Body

chr17

cg13274938

38,493,822

2.63 (1.68, 3.57)

2.98 (− 0.74, 6.70)

0.115

2.65 (1.73, 3.56)

1.46E-08

0.854

N Shelf

RARA

Body

chr21

cg06500161**

43,656,587

2.93 (2.19, 3.67)

5.32 (2.60, 8.04)

0.0002

3.10 (2.39, 3.81)

1.53E-17

0.092

S Shore

ABCG1

Body

chr21

cg08309687£

35,320,596

− 1.58 (− 2.08, − 1.08)

− 2.24 (− 4.53, 0.06)

0.056

− 1.61 (-2.10, − 1.12)

9.62E-11

0.579

OpenSea

 

Intergenic

chr21

cg27243685**

43,642,366

3.12 (2.08, 4.16)

8.91 (3.96, 13.87)

0.001

3.37 (2.35, 4.39)

8.95E-11

0.023

S Shelf

ABCG1

Body

chr22

cg09349128

50,327,986

− 2.46 (− 3.41, − 1.50)

− 2.72 (− 5.34, -0.10)

0.042

− 2.49 (− 3.38, − 1.59)

4.61E-08

0.852

N Shore

 

Intergenic

  1. Chr Chromosome, CI Confidence interval, CpG CpG dinucleotide, Effect Effect size; TSS200, 0–200 bp upstream of transcription start site; TSS1500, 200–1500 bp upstream of transcription start site; UTR, untranslated region. Numbers in bold face are statistically significant
  2. § Annotation used R v.0.6.0.IlluminaHumanMethylation450kanno.ilmn12.hg19: Annotation for Illumina's 450 k methylation arrays
  3. † Each effect size of the CpGs in the discovery stage was at the epigenome-wide significance level (p < 1E-007)
  4. a Effect size adjusted by age and leukocyte heterogeneities (CD8+CD28−CD45RA− T cell, naïve CD8 T cell, plasma blast, CD4+ T cell, natural killer cell, monocyte, and granulocyte)
  5. ¥ p value for Cochran’s Q
  6. * Promoter associated
  7. ** Enhancer associated
  8. £ Enhancer and promoter associated